Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

Sam Pearson,1,* Noppadol Kietsiriroje,1,2,* Ramzi A Ajjan1 1Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, West Yorkshire LS2 9JT, UK; 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicin...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pearson S, Kietsiriroje N, Ajjan RA
Format: article
Langue:EN
Publié: Dove Medical Press 2019
Sujets:
Accès en ligne:https://doaj.org/article/ea897ea817234a6793c6e8fcf10e6798
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!